Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasma...
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
The purpose of this study is to determine the very good partial response (VGPR) or better rate in participants with Waldenström macroglobulinemia (WM). The names of the study drugs involved in this s...
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The names ...
Loncastuximab Tesirine in WM
This study is being done to examine the safety and effectiveness of loncastuximab tesirine as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The name of the study drug...
Epcoritamab in Previously Treated WM
This study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM). The names of the study drug involved in this study i...
Top Cities for Waldenstrom Macroglobulinemia Clinical Trials
Waldenstrom Macroglobulinemia clinical trials are recruiting across 11 cities. Here are the cities with the most active studies:
About Waldenstrom Macroglobulinemia
Waldenstrom macroglobulinemia is a rare type of non-Hodgkin lymphoma where cancer cells produce large amounts of an abnormal protein called macroglobulin. It progresses slowly and may not require immediate treatment. Options include targeted therapy, chemotherapy, and plasmapheresis.
Clinical trials are advancing new treatments for waldenstrom macroglobulinemia. Currently, 5 studies are recruiting a combined 245 participants across the United States. Research is being conducted by 5 organizations including National Cancer Institute (NCI), Massachusetts General Hospital, Dana-Farber Cancer Institute and 2 others.
2026 Waldenstrom Macroglobulinemia Research Landscape
As of March 2026, the waldenstrom macroglobulinemia clinical trial landscape includes 5 actively recruiting studies across 11 cities in the United States. These studies are collectively seeking 245 participants, with an average enrollment target of 49 per study.
Research is being led by 5 different organizations, including National Cancer Institute (NCI), Massachusetts General Hospital, Dana-Farber Cancer Institute, Shayna Sarosiek, MD, Gottfried von Keudell, MD PhD.
Geographically, waldenstrom macroglobulinemia trials are most concentrated in Boston, Massachusetts (10 trials); Tucson, Arizona (2 trials); Effingham, Illinois (2 trials); Jacksonville, Florida (1 trial); Centralia, Illinois (1 trial) and 6 other cities.
Featured Waldenstrom Macroglobulinemia Studies
Highlighted recruiting studies for waldenstrom macroglobulinemia, selected by enrollment size and research scope.
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is fo...
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
The purpose of this study is to determine the very good partial response (VGPR) or better rate in participants with Waldenström macroglobulinemia (WM). The names of the study drugs involved in this study are as follows: zanubrutinib, bendamustine, and rituximab.
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The names of the study drugs involved in this study are: * Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor) * Venetoclax (a BCL2 inhibitor)
Frequently Asked Questions About Waldenstrom Macroglobulinemia Clinical Trials
Are there waldenstrom macroglobulinemia clinical trials near me?
Yes, there are 5 waldenstrom macroglobulinemia clinical trials currently recruiting across 11+ cities in the United States, including Boston, Massachusetts; Tucson, Arizona; Effingham, Illinois. Browse the studies above to find one at a location convenient for you.
How do I join a waldenstrom macroglobulinemia clinical trial?
To join a waldenstrom macroglobulinemia clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are waldenstrom macroglobulinemia clinical trials free?
Yes, participation in waldenstrom macroglobulinemia clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of waldenstrom macroglobulinemia treatments are being studied?
Current waldenstrom macroglobulinemia clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 5 research organizations.
Is it safe to participate in waldenstrom macroglobulinemia clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov